Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raphael Itzykson

Showing results (51-60 of 97) with videos related to

Pageof 10
Sort By:
Haematologica|September 6, 2015
An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasmsTariq I Mughal, Nicholas C P Cross, Eric Padron, et al.
Communications Biology|February 4, 2022
Macrophage migration inhibitory factor is overproduced through EGR1 in TET2<sup>low</sup> resting monocytesElodie Pronier, Aygun Imanci, Dorothée Selimoglu-Buet, et al.
Blood|August 19, 2022
Azithromycin promotes relapse by disrupting immune and metabolic networks after allogeneic stem cell transplantationNicolas Vallet, Sophie Le Grand, Louise Bondeelle, et al.
Ebiomedicine|May 6, 2018
Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating AgentsMatthieu Duchmann, Fevzi F Yalniz, Alessandro Sanna, et al.
Leukemia Research|December 20, 2014
Azacitidine for the treatment of relapsed and refractory AML in older patientsRaphael Itzykson, Sylvain Thépot, Céline Berthon, et al.
Blood|August 11, 2011
Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trialThorsten Braun, Raphael Itzykson, Aline Renneville, et al.
Leukemia|October 7, 2021
Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AMLMatthieu Duchmann, Orianne Wagner-Ballon, Thomas Boyer, et al.
Nature Genetics|March 24, 2020
Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancerKevin H Lin, Justine C Rutter, Abigail Xie, et al.
Leukemia & Lymphoma|August 26, 2017
Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+)José Falantes, Lisa Pleyer, Sylvain Thépot, et al.
Leukemia|March 22, 2019
Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemiaNolwenn Lucas, Matthieu Duchmann, Philippe Rameau, et al.
Pageof 10

Showing results (51-60 of 97) with videos related to

Sort By:
Pageof 10
Haematologica|September 6, 2015
An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasmsTariq I Mughal, Nicholas C P Cross, Eric Padron, et al.
Communications Biology|February 4, 2022
Macrophage migration inhibitory factor is overproduced through EGR1 in TET2<sup>low</sup> resting monocytesElodie Pronier, Aygun Imanci, Dorothée Selimoglu-Buet, et al.
Blood|August 19, 2022
Azithromycin promotes relapse by disrupting immune and metabolic networks after allogeneic stem cell transplantationNicolas Vallet, Sophie Le Grand, Louise Bondeelle, et al.
Ebiomedicine|May 6, 2018
Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating AgentsMatthieu Duchmann, Fevzi F Yalniz, Alessandro Sanna, et al.
Leukemia Research|December 20, 2014
Azacitidine for the treatment of relapsed and refractory AML in older patientsRaphael Itzykson, Sylvain Thépot, Céline Berthon, et al.
Blood|August 11, 2011
Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trialThorsten Braun, Raphael Itzykson, Aline Renneville, et al.
Leukemia|October 7, 2021
Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AMLMatthieu Duchmann, Orianne Wagner-Ballon, Thomas Boyer, et al.
Nature Genetics|March 24, 2020
Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancerKevin H Lin, Justine C Rutter, Abigail Xie, et al.
Leukemia & Lymphoma|August 26, 2017
Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+)José Falantes, Lisa Pleyer, Sylvain Thépot, et al.
Leukemia|March 22, 2019
Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemiaNolwenn Lucas, Matthieu Duchmann, Philippe Rameau, et al.
Pageof 10